Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study

Liqi Shu1, Ekaterina Bakradze1, Setareh Salehi Omran1

  • 1From the Department of Neurology (L.S., C.S., N.K., S.E., A.C., S.C., F.I., K.F., Shadi Yaghi), Brown University, Providence, RI; Department of Neurology (E.B.), University of Alabama at Birmingham; Department of Neurology (S.S.O.), University of Colorado School of Medicine, Aurora; Department of Neurology (J.G., J.A.), Washington University, Saint Louis, MO; Departments of Neurology (N.H., M.D.M.), and Psychiatry (N.H.), University of Massachusetts, Worcester; Department of Neurology (A.L.), Weill Cornell Medical Center, New York, NY; Department of Neurology (K.M., J.R.), Montefiore Medical Center, New York, NY; Department of Neurology (R.S., Yee Cheng, A.S.Z., A.H.), Yale University, New Haven, CT; Department of Neurology (Alexis Simpkins, G.L., J.K., D.P.), University of Florida, Gainesville; Department of Neurology (M.R.H., Adrian Scutelnic, R.M., B.S.), Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; Department of Neurology (A.R., O.K., D.D.), University of Pennsylvania, Philadelphia; Departments of Neurology (S.A.K., L.A.R.) and Neurosurgery (S.A.K.), Medical University of South Carolina, Charleston; Department of Neurology and Rehabilitation Medicine (E.A.M., Pooja Khatri, Y.A., B.C.), University of Cincinnati; Department of Neurology (D.K., H.L.), Vanderbilt University, Nashville, TN; Department of Neurology (T.N.N., Piers Klein, H.J.A.), Boston University School of Medicine, MA; Department of Neurology (J.A.F., L.K., S.A.), New York University, NY; Department of Neurology (V.M.), University of Utah, Salt Lake City; Department of Neurology (T.W., D.W.), Christchurch Hospital, New Zealand; Department of Neurology (A.N., D.A.), Hartford Hospital, CT; Department of Neurology (A.Q., J.M.), University of Kansas, Kansas City; Department of Neurology (M.K., Yao Cheng), Spectrum Health, Michigan State University, Grand Rapids, MI; Department of Neurology (B.M.G., M.W., D.R.), Duke University, Durham, NC; Department of Medicine and Surgery (M.C.V.), University of Perugia, Italy, University of Perugia, Italy; Neurology-Stroke Unit (Maurizio Paciaroni), IRCCS MultiMedica, Milano, Italy; Cooper Neurologic Institute (J.S., S.K., Siyuan Yu), Cooper University, Camden, NJ; Department of Neurology (C.L.G., E.A.), George Washington University, District of Columbia; Department of Neurology (G.M.D.M., T.D.), University Hospital Basel and University of Basel, Switzerland; Department of Interventional and Diagnostic Neuroradiology (A.B., Marios Psychogios), Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Switzerland; Department of Neurology (R.A.-D., T.K.-H., S.P.), University of Chicago, IL; and Department of Neurology (T.H., D.L.), University of California at Los Angeles.

Neurology
|September 19, 2022
PubMed
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
37
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
29
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
19
Venous Return01:04

Venous Return

The circulatory system plays a crucial role in ensuring the optimal functioning of the human body. One of its critical components is venous return - the process that completes the blood circulation cycle. This article will delve into the concept of venous return, how it works, and its significance to our health.
What is Venous Return?
Venous return refers to the rate at which blood flows back to the heart from the body's peripheral veins. It's an integral part of the circulatory system...
5.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K